Axonics® Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
With this exercise, the total number of shares of common stock sold by
Axonics in the offering increased to 9,200,000 shares, representing
total gross proceeds of
Axonics’ common stock began trading on The Nasdaq Global Select Market
under the ticker symbol “AXNX” on
BofA Merrill Lynch and
A registration statement on Form S-1, including a prospectus relating to
the offering, was filed with, and declared effective by, the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About
Axonics has developed an innovative rechargeable SNM system for the
treatment of patients with OAB, FI, and UR. Axonics’ proprietary r-SNM
System is designed to be 60% smaller than existing technology and to
last approximately 15 years. Axonics currently has marketing approvals
in
View source version on businesswire.com: https://www.businesswire.com/news/home/20181119005523/en/
Source:
Axonics’ Contact
Axonics Modulation Technologies, Inc.
Dan
Dearen, +1-949-396-6320
President & Chief Financial Officer
ir@axonics.com
Investor
& Media Contact
W2Opure
Matt Clawson, +1-949-370-8500
mclawson@w2ogroup.com